Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 19, 2026.

A consensus on the diagnosis and treatment of acromegaly complications

S. Melmed, F. F. Casanueva, A. Klibanski and 6 more (opens in a new tab)

Pituitary · 2012

doi:10.1007/s11102-012-0420-x (opens in a new tab)

Abstract

In March 2011, the Acromegaly Consensus Group met to revise and update the guidelines on the diagnosis and treatment of acromegaly complications. The meeting was sponsored by the Pituitary Society and the European Neuroendocrinology Association and included experts skilled in the management of acromegaly. Complications considered included cardiovascular, endocrine and metabolic, sleep apnea, bone diseases, and mortality. Outcomes in selected, related clinical conditions were also considered, and included pregnancy, familial acromegaly and invasive macroadenomas. The need for a new disease staging model was considered, and design of such a tool was proposed.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 19, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Since 2000, several consensus documents have been published on various aspects of acromegaly management. In 2003 a consensus on the diagnosis and treatment of acromegaly complications was published, and in March 2011, the Acromegaly Consensus Group that had produced these documents met to revise and update guidelines on acromegaly complications. The meeting was sponsored by the Pituitary Society and the European Neuroendocrinology Association and included experts skilled in acromegaly management.

Patients with acromegaly have a considerable burden of complications and co-existing illnesses, and factors contributing to increased mortality in acromegaly include higher prevalence of hypertension, hyperglycemia or diabetes, cardiomyopathy and sleep apnea. The diagnosis and management of complications of disease are therefore critical for assuring a favorable long-term outcome for this chronic illness. Current comorbidity issues were discussed by the group and recommendations made for updating the 2003 guidelines.

Recommendations were graded, based on the GRADE system, depending on the quality of evidence as very low quality (VLQ; expert opinion with one or a small number of small uncontrolled studies in support), low quality (LQ; large series of small uncontrolled studies), moderate quality (MQ; one or a small number of large uncontrolled studies or meta-analyses), or high quality (HQ; controlled studies or large series of large uncontrolled studies with sufficiently long follow-up). Recommendations were classed as discretionary recommendations (DR) if based on VLQ or LQ evidence, and as strong recommendations (SR) if based on MQ and HQ evidence.

Cardiovascular complications

Hypertension is highly prevalent, occurring in more than 40 % of patients with acromegaly, and early diagnosis and early aggressive treatment of elevated blood pressure is important irrespective of which acromegaly treatment is employed (HQ). Hypertension in patients with acromegaly is usually mild and readily treated with anti-hypertensive drugs (VLQ). The choice of treatment for hypertension should be similar to that in non-acromegaly patients (DR). The effect of different medical treatments for acromegaly on hypertension is as yet unclear (LQ). Sleep apnea, which is present in most patients with acromegaly, exacerbates hypertension (LQ).

Cardiomyopathy is present in most patients with acromegaly, and baseline echocardiogram is indicated. Arrhythmia is rarely a significant clinical challenge in acromegaly (MQ). Treatment of acromegaly improves early and intermediate stage myocardial hypertrophy and cardiac dysfunction (HQ). Improvement depends on age, presence of hypertension and duration of the disease (LQ). Recent data (published after the consensus meeting) show that cabergoline does not aggravate prevalence or incidence of valve regurgitation and remodeling, which are increased in acromegaly (MQ). Furthermore, somatostatin receptor ligands (SRLs) may cause asymptomatic bradycardia (LQ). Rigorous clinical outcome measures (and not only biochemical goals) should be addressed in research studies.

The following routine baseline assessments are therefore required for patients with acromegaly: electrocardiogram (ECG), echocardiogram, blood pressure measurement, and the Epworth scale or sleep study for sleep apnea (SR) (Table 1). These patients also require assessment of the peripheral arterial system. Particularly in gigantism, there is a need for assessment of vascular disease including peripheral venous disease (DR).

Diabetes

Diabetes occurs more frequently in acromegaly patients than in the general population and is an important predictive factor for increased mortality in patients with acromegaly (HQ). Treatment of diabetes should be the same in patients with or without acromegaly (DR). Generally, lowering of growth hormone (GH) levels improves glycemic control and enhances insulin sensitivity (GH is a powerful insulin antagonist), whatever mode of treatment is used (MQ). An exacerbation of carbohydrate intolerance may occur rarely in patients receiving SRLs (MQ) (but hyperglycemia occurs more frequently with pasireotide than with other SRLs) and pegvisomant may be considered for treatment of these patients (DR).

Hypogonadism

Hypogonadism occurs in approximately 50 % of acromegaly patients, but is often reversible unless gonadotroph destruction has occurred (MQ). Biochemical diagnosis in males may be difficult, due to low sex hormone-binding globulin levels (making interpretation of total testosterone values more challenging) (LQ). In these circumstances, assessment of clinical symptoms and bioavailable testosterone are important for diagnosis (DR) (Table 1). Concomitant hyperprolactinemia should be considered as a cause of hypogonadism (MQ). Treatment indications for hypogonadism in acromegaly, and the specific therapy used, should be similar to the non-acromegaly population (DR). In women, hypogonadism should be assessed carefully and treated appropriately, especially if fertility is desired (SR).

Sleep apnea

Sleep apnea is currently under-assessed, and the prevalence is high (up to 70 %) in newly diagnosed patients with acromegaly (MQ). Therefore, every patient should have a careful symptomatic assessment (e.g., by Epworth score), and if necessary laboratory assessment, for sleep apnea at the time of diagnosis, in collaboration with a respiratory physician (SR).

Despite successful acromegaly treatment, sleep apnea does not consistently resolve (MQ), so post-treatment evaluation is essential (SR). Every effort should be made to improve compliance with prescribed treatments including continuous positive air pressure device and other devices (e.g., with appropriate measures tailored to patients with acromegaly, for example, specialized mouth pieces for use during sleep). Consultation with maxillo-facial surgeons is advised, and if necessary, elective surgery should be undertaken.

Quality of life

Quality of life (QoL) is an important outcome measure in acromegaly. Tools for measuring QoL in patients with acromegaly (e.g., Acromegaly Quality of Life Questionnaire [AcroQoL]) are readily available and should be considered in clinical practice (MQ) (Table 1). QoL is impaired by GH-excess and GH-deficiency, and therefore, when treating patients, it is important to recognize induction of GH-deficiency, particularly in patients who have undergone previous radiation therapy, as this can have further deleterious effects on subsequent QoL and other parameters (DR).

Bones and joints

Arthropathy affects approximately 75 % of acromegaly patients. Any joint may be affected (large joints, small joints and vertebrae), and range from osteoarthritis to arthralgia to fractures (HQ). Bony overgrowth and soft-tissue swelling may also lead to nerve entrapment. Such anatomical abnormalities may result in a delay to surgical intervention for acromegaly (LQ). Disability due to acromegaly is probably under-estimated and can affect many aspects of activities of daily living (MQ). Early diagnosis of acromegaly is required to ensure early and aggressive treatment to reduce arthropathy risk, because joint and cartilage changes are irreversible (SR).

Vertebral fractures have been reported to occur in acromegaly patients independently of bone mineral density (BMD) (MQ). Bone size may affect BMD measurement, and the utility of dual-energy X-ray absorptiometry for screening for abnormalities in the absence of size correction is not well documented (LQ). Thoracic and lumbar spine X-ray may be useful for diagnosing spinal deformities, particularly in symptomatic patients (DR) (Table 1). Patients with acromegaly should be evaluated for osteoporosis risk factors including vitamin D deficiency, inadequate calcium intake, serum calcium to assess hyperparathyroidism, glucocorticoid over-replacement and hypogonadism (SR).

Colon polyps

Acromegaly is associated with increased colon polyps and may be associated with increased risk of colorectal cancer, but not cancer mortality (MQ). Colon length may increase during acromegaly resulting in increased mucosal folds (dolichocolon) (LQ). It is recommended that a screening colonoscopy be carried out at diagnosis in adults (SR). If the colonoscopy is negative, then patients should be screened similarly to the general population, especially if insulin-like growth factor-I (IGF-I) levels are normalized (DR) (Table 1). If IGF-I remains persistently elevated, more frequent screening is recommended (SR). If colonoscopy is abnormal, follow-up and screening should be in accordance with clinical guidelines.

Mortality

Uncontrolled acromegaly is associated with increased mortality (HQ). Co-existing adrenal insufficiency and its therapy may have an impact on mortality (LQ). In comparison with other forms of treatment aimed at controlling GH hypersecretion, conventional radiation therapy is specifically associated with increased overall mortality (MQ). Radiation therapy increases risk of hypopituitarism that leads to higher mortality; including cerebrovascular disease (MQ). There is a need for more data on mortality outcomes in patients receiving stereotactic radiation therapy, which will become available as more patients are followed-up in the long term.

Minimal dose of glucocorticoids required for efficacy in hypopituitarism should be used, as over-replacement of glucocorticoids can have a negative impact on mortality (LQ). Attention to the GH status is important when using glucocorticoid replacement therapy because higher replacement doses may be required when GH therapy is given (DR).

Improved medical therapy is recommended to control GH/IGF-I levels and improve mortality (SR). Gonadal, thyroid and GH deficiencies should also be assessed and properly replaced, when indicated (SR).

Pregnancy

In women with acromegaly who wish to become pregnant, pituitary function should be assessed and surgical or medical treatment initiated as indicated (SR). There are few data (animal or human) on the safety of pegvisomant in pregnancy (VLQ).

Unless clinically indicated, pharmacological agents should be discontinued on confirmation of pregnancy (SR). In some pregnant women, IGF-I levels remain within the normal range (for non-pregnant women), even in uncontrolled patients, and then increase after delivery. Biochemical assessment of disease activity is of limited value because of placental production of GH and IGF-I (LQ). There is a need to encourage reporting of outcomes in medically treated pregnant women with acromegaly.

Familial acromegaly

Familial acromegaly is generally diagnosed at an earlier age than non-familial acromegaly, and young patients (<30 years old) with aggressive acromegaly, or individuals with a family member who has a pituitary tumor, should be considered for genetic screening for markers of familial acromegaly (DR). Carney complex, familial isolated pituitary adenoma (FIPA) and multiple endocrine neoplasia type 1 should be considered (DR). An increased awareness that FIPA is associated with mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene is required.

Invasive macroadenomas

Access to multimodal treatment and involvement of a multi-disciplinary team are needed in patients with invasive macroadenomas (HQ). If visual fields are impaired, immediate surgery is typically the first line therapy (HQ). Pre-treatment with SRL may improve subsequent surgical outcomes (MQ). Surgical debulking may improve subsequent medical treatment outcomes (LQ). Radiation therapy may continue to have a place in the acromegaly treatment algorithm (MQ). The choice of treatment strategy should include consideration of comorbidities, the projected length of time for hormone normalization, therapy side-effects, pituitary function and cost-benefit of the indicated strategy (DR).

Biochemical control

Over the past decade, biochemical criteria defining ‘control’ of disease activity have become increasingly rigorous. The most recent definitions of active disease (random GH ≥1 ng/ml; nadir GH after oral glucose tolerance test (OGTT) ≥0.4 ng/ml; and elevated IGF-I for age) and optimal disease control (random GH <1 ng/ml when treated with SRLs; nadir GH after OGTT <0.4 ng/ml after surgery; and age-normalized IGF-I levels for all treatments and as a unique parameter with pegvisomant usage) remain valid (SR). However, the definition for optimal disease control comes with the caveat that assay-specific normative data for post-OGTT nadir are required (DR).

Tumor control

The role of tumor characteristics and of optimal tumor growth control has not been fully agreed by consensus. Factors proposed to be associated with disease persistence after surgery and/or a sub-optimal response to medical therapy include:Younger age at diagnosis (LQ).High expression of tumor aggression markers like Ki67, p53 and pituitary tumor transforming gene (PTTG) (LQ).Sparsely granulated adenomas and hyper-intense imaging on T2 weighted magnetic resonance imaging (MQ).Very large adenomas and actively growing tumors (MQ).No previous radiation therapy, especially during pegvisomant therapy (LQ).Previous, sub-optimal response to SRL therapy (LQ).High GH and IGF-I levels during long-term follow-up (HQ).Larger tumor remnants after surgery (MQ).

Younger age at diagnosis (LQ).

High expression of tumor aggression markers like Ki67, p53 and pituitary tumor transforming gene (PTTG) (LQ).

Sparsely granulated adenomas and hyper-intense imaging on T2 weighted magnetic resonance imaging (MQ).

Very large adenomas and actively growing tumors (MQ).

No previous radiation therapy, especially during pegvisomant therapy (LQ).

Previous, sub-optimal response to SRL therapy (LQ).

High GH and IGF-I levels during long-term follow-up (HQ).

Larger tumor remnants after surgery (MQ).

The need for a staging tool?

A new model for describing overall patient assessment before and during treatment would be valuable. The rationale supporting the need for such a model is the requirement to integrate a number of clinical metrics as well as information on pituitary tumor characteristics with the currently used biochemical markers. Ideally, such a model should include data on:Clinical symptoms.Associated clinical signs and comorbidities.GH level.IGF-I level.Tumor size.

Clinical symptoms.

Associated clinical signs and comorbidities.

GH level.

IGF-I level.

Tumor size.

Conclusions

Effective management of acromegaly complications will lead to decreased morbidity and mortality, and improved QoL. Comprehensive multimodal acromegaly management should integrate biochemical monitoring, careful assessment of tumor behavior and clinical features, and comorbidities.

References 116

  1. 1.

    Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000;85(2):526-529.

    Not in our library10.1210/jc.85.2.526 (opens in a new tab)

  2. 2.

    Giustina A, Barkan A, Chanson P, Grossman A, Hoffman A, Ghigo E, Casanueva F, Colao A, Lamberts S, Sheppard M, Melmed S. Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J Endocrinol Invest. 2008;31(9):820-838.

    Not in our library10.1007/bf03349263 (opens in a new tab)

  3. 3.

    Giustina A, Casanueva FF, Cavagnini F, Chanson P, Clemmons D, Frohman LA, Gaillard R, Ho K, Jaquet P, Kleinberg DL, Lamberts SW, Lombardi G, Sheppard M, Strasburger CJ, Vance ML, Wass JA, Melmed S. Diagnosis and treatment of acromegaly complications. J Endocrinol Invest. 2003;26(12):1242-1247.

    Not in our library10.1007/bf03349164 (opens in a new tab)

  4. 4.

    Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95(7):3141-3148.

    Not in our library10.1210/jc.2009-2670 (opens in a new tab)

  5. 5.

    Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JA, Giustina A. Consensus statement: medical management of acromegaly. Eur J Endocrinol. 2005;153(6):737-740.

    Not in our library10.1530/eje.1.02036 (opens in a new tab)

  6. 6.

    Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A. Guidelines for acromegaly management. J Clin Endocrinol Metab. 2002;87(9):4054-4058.

    Not in our library10.1210/jc.2002-011841 (opens in a new tab)

  7. 7.

    Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94(5):1509-1517.

    Not in our library10.1210/jc.2008-2421 (opens in a new tab)

  8. 8.

    Melmed S. Medical progress: acromegaly. N Engl J Med. 2006;355(24):2558-2573.

    Not in our library10.1056/nejmra062453 (opens in a new tab)

  9. 9.

    Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF, Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(9):3266-3281.

    Not in our library10.1210/jc.2008-0104 (opens in a new tab)

  10. 10.

    Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926.

    Not in our library10.1136/bmj.39489.470347.ad (opens in a new tab)

  11. 11.

    Vitale G, Pivonello R, Auriemma RS, Guerra E, Milone F, Savastano S, Lombardi G, Colao A. Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin Endocrinol. 2005;63(4):470-476.

    Not in our library10.1111/j.1365-2265.2005.02370.x (opens in a new tab)

  12. 12.

    Bihan H, Espinosa C, Valdes-Socin H, Salenave S, Young J, Levasseur S, Assayag P, Beckers A, Chanson P. Long-term outcome of patients with acromegaly and congestive heart failure. J Clin Endocrinol Metab. 2004;89(11):5308-5313.

    Not in our library10.1210/jc.2004-0821 (opens in a new tab)

  13. 13.

    Cannavo S, Almoto B, Cavalli G, Squadrito S, Romanello G, Vigo MT, Fiumara F, Benvenga S, Trimarchi F. Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography. J Clin Endocrinol Metab. 2006;91(10):3766-3772.

    Not in our library10.1210/jc.2005-2857 (opens in a new tab)

  14. 14.

    Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25(1):102-152.

    Not in our library10.1210/er.2002-0022 (opens in a new tab)

  15. 15.

    Colao A, Spinelli L, Marzullo P, Pivonello R, Petretta M, Di Somma C, Vitale G, Bonaduce D, Lombardi G. High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J Clin Endocrinol Metab. 2003;88(7):3196-3201.

    Not in our library10.1210/jc.2002-021099 (opens in a new tab)

  16. 16.

    Maffei P, Martini C, Milanesi A, Corfini A, Mioni R, de Carlo E, Menegazzo C, Scanarini M, Vettor R, Federspil G, Sicolo N. Late potentials and ventricular arrhythmias in acromegaly. Int J Cardiol. 2005;104(2):197-203.

    Not in our library10.1016/j.ijcard.2004.12.010 (opens in a new tab)

  17. 17.

    van der Klaauw AA, Bax JJ, Roelfsema F, Bleeker GB, Holman ER, Corssmit EP, van der Wall EE, Smit JW, Romijn JA, Pereira AM. Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. Growth Horm IGF Res. 2006;16(2):101-107.

    Not in our library10.1016/j.ghir.2006.02.002 (opens in a new tab)

  18. 18.

    Andreassen M, Faber J, Kjaer A, Petersen CL, Kristensen LO. Cardiac effects of 3 months treatment of acromegaly evaluated by magnetic resonance imaging and B-type natriuretic peptides. Pituitary. 2010;13(4):329-336.

    Not in our library10.1007/s11102-010-0240-9 (opens in a new tab)

  19. 19.

    Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab. 2004;89(4):1613-1617.

    Not in our library10.1210/jc.2003-031584 (opens in a new tab)

  20. 20.

    Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, Loyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman UH, Viikari J, Voutilainen E. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab. 2005;90(7):4081-4086.

    Not in our library10.1210/jc.2004-1381 (opens in a new tab)

  21. 21.

    Pivonello R, Galderisi M, Auriemma RS, De Martino MC, Galdiero M, Ciccarelli A, D’Errico A, Kourides I, Burman P, Lombardi G, Colao A. Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J Clin Endocrinol Metab. 2007;92(2):476-482.

    Not in our library10.1210/jc.2006-1587 (opens in a new tab)

  22. 22.

    Davi MV, Dalle Carbonare L, Giustina A, Ferrari M, Frigo A, Lo Cascio V, Francia G. Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol. 2008;159(5):533-540.

    Not in our library10.1530/eje-08-0442 (opens in a new tab)

  23. 23.

    Colao A, Pivonello R, Grasso LF, Auriemma RS, Galdiero M, Savastano S, Lombardi G. Determinants of cardiac disease in newly diagnosed patients with acromegaly. Results of a 10 year survey study. Eur J Endocrinol. 2011;165(5):713-721.

    Not in our library10.1530/eje-11-0408 (opens in a new tab)

  24. 24.

    Colao A, Marek J, Goth MI, Caron P, Kuhn JM, Minuto FM, Weissman NJ. No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly. J Clin Endocrinol Metab. 2008;93(6):2243-2248.

    Not in our library10.1210/jc.2007-2199 (opens in a new tab)

  25. 25.

    Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2007;92(5):1743-1747.

    Not in our library10.1210/jc.2006-2547 (opens in a new tab)

  26. 26.

    De Marinis L, Bianchi A, Mazziotti G, Mettimano M, Milardi D, Fusco A, Cimino V, Maira G, Pontecorvi A, Giustina A. The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly. Pituitary. 2008;11(1):13-20.

    Not in our library10.1007/s11102-007-0062-6 (opens in a new tab)

  27. 27.

    Maione L, Garcia C, Bouchachi A, Kallel N, Maison P, Salenave S, Young J, Assayag P, Chanson P (2012) No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly. J Clin Endocrinol Metab. doi:10.1210/jc.2012-1833

    Not in our library10.1210/jc.2012-1833 (opens in a new tab)

  28. 28.

    Colao A. Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. Pituitary. 2012;15(1):50-58.

    Not in our library10.1007/s11102-011-0318-z (opens in a new tab)

  29. 29.

    Lafeber M, Stades AM, Valk GD, Cramer MJ, Teding van Berkhout F, Zelissen PM. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. Eur J Endocrinol. 2010;162(4):667-675.

    Not in our library10.1530/eje-09-0989 (opens in a new tab)

  30. 30.

    Erem C, Ersoz HO, Ukinc K, Avunduk AM, Hacihasanoglu A, Kocak M. Acromegaly presenting with diabetic ketoacidosis, associated with retinitis pigmentosa and octreotide-induced bradycardia: a case report and a review of the literature. Endocrine. 2006;30(1):145-149.

    Not in our library10.1385/endo:30:1:145 (opens in a new tab)

  31. 31.

    Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon-Alonso A, Sheppard MC, Bates AS, Stewart PM. Mortality in patients with pituitary disease. Endocr Rev. 2010;31(3):301-342.

    Not in our library10.1210/er.2009-0033 (opens in a new tab)

  32. 32.

    Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol. 1994;41(1):95-102.

    Not in our library10.1111/j.1365-2265.1994.tb03789.x (opens in a new tab)

  33. 33.

    Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab. 2009;94(5):1500-1508.

    Not in our library10.1210/jc.2008-2332 (opens in a new tab)

  34. 34.

    Mazziotti G, Porcelli T, Bogazzi F, Bugari G, Cannavo S, Colao A, Cozzi R, De Marinis L, De Degli Uberti E, Grottoli S, Minuto F, Montini M, Spinello M, Giustina A. Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. Eur J Endocrinol. 2011;164(3):341-347.

    Not in our library10.1530/eje-10-0811 (opens in a new tab)

  35. 35.

    Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho YY, Hu K, Farrall AJ, Melmed S, Biller BM. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab. 2010;95(6):2781-2789.

    Not in our library10.1210/jc.2009-2272 (opens in a new tab)

  36. 36.

    Grynberg M, Salenave S, Young J, Chanson P. Female gonadal function before and after treatment of acromegaly. J Clin Endocrinol Metab. 2010;95(10):4518-4525.

    Not in our library10.1210/jc.2009-2815 (opens in a new tab)

  37. 37.

    Katznelson L, Kleinberg D, Vance ML, Stavrou S, Pulaski KJ, Schoenfeld DA, Hayden DL, Wright ME, Woodburn CJ, Klibanski A. Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study. Clin Endocrinol. 2001;54(2):183-188.

    Not in our library10.1046/j.1365-2265.2001.01214.x (opens in a new tab)

  38. 38.

    van Haute FR, Taboada GF, Correa LL, Lima GA, Fontes R, Riello AP, Dominici M, Gadelha MR. Prevalence of sleep apnea and metabolic abnormalities in patients with acromegaly and analysis of cephalometric parameters by magnetic resonance imaging. Eur J Endocrinol. 2008;158(4):459-465.

    Not in our library10.1530/eje-07-0753 (opens in a new tab)

  39. 39.

    Attal P, Chanson P. Endocrine aspects of obstructive sleep apnea. J Clin Endocrinol Metab. 2010;95(2):483-495.

    Not in our library10.1210/jc.2009-1912 (opens in a new tab)

  40. 40.

    Sze L, Schmid C, Bloch KE, Bernays R, Brandle M. Effect of transsphenoidal surgery on sleep apnoea in acromegaly. Eur J Endocrinol. 2007;156(3):321-329.

    Not in our library10.1530/eje.1.02340 (opens in a new tab)

  41. 41.

    Grunstein RR, Ho KK, Sullivan CE. Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med. 1994;121(7):478-483.

    Not in our library10.7326/0003-4819-121-7-199410010-00002 (opens in a new tab)

  42. 42.

    Herrmann BL, Wessendorf TE, Ajaj W, Kahlke S, Teschler H, Mann K. Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. Eur J Endocrinol. 2004;151(3):309-315.

    Not in our library10.1530/eje.0.1510309 (opens in a new tab)

  43. 43.

    Ip MS, Tan KC, Peh WC, Lam KS. Effect of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clin Endocrinol. 2001;55(4):477-483.

    Not in our library10.1046/j.1365-2265.2001.01358.x (opens in a new tab)

  44. 44.

    Matta MP, Couture E, Cazals L, Vezzosi D, Bennet A, Caron P. Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance. Eur J Endocrinol. 2008;158(3):305-310.

    Not in our library10.1530/eje-07-0697 (opens in a new tab)

  45. 45.

    Neggers SJ, van Aken MO, de Herder WW, Feelders RA, Janssen JA, Badia X, Webb SM, van der Lely AJ. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab. 2008;93(10):3853-3859.

    Not in our library10.1210/jc.2008-0669 (opens in a new tab)

  46. 46.

    Wexler T, Gunnell L, Omer Z, Kuhlthau K, Beauregard C, Graham G, Utz AL, Biller B, Nachtigall L, Loeffler J, Swearingen B, Klibanski A, Miller KK. Growth hormone deficiency is associated with decreased quality of life in patients with prior acromegaly. J Clin Endocrinol Metab. 2009;94(7):2471-2477.

    Not in our library10.1210/jc.2008-2671 (opens in a new tab)

  47. 47.

    Killinger Z, Payer J, Lazurova I, Imrich R, Homerova Z, Kuzma M, Rovensky J. Arthropathy in acromegaly. Rheum Dis Clin North Am. 2010;36(4):713-720.

    Not in our library10.1016/j.rdc.2010.09.004 (opens in a new tab)

  48. 48.

    Bonadonna S, Mazziotti G, Nuzzo M, Bianchi A, Fusco A, De Marinis L, Giustina A. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res. 2005;20(10):1837-1844.

    Not in our library10.1359/jbmr.050603 (opens in a new tab)

  49. 49.

    Wassenaar MJ, Biermasz NR, Hamdy NA, Zillikens MC, van Meurs JB, Rivadeneira F, Hofman A, Uitterlinden AG, Stokkel MP, Roelfsema F, Kloppenburg M, Kroon HM, Romijn JA, Pereira AM. High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. Eur J Endocrinol. 2011;164(4):475-483.

    Not in our library10.1530/eje-10-1005 (opens in a new tab)

  50. 50.

    Podgorski M, Robinson B, Weissberger A, Stiel J, Wang S, Brooks PM. Articular manifestations of acromegaly. Aust N Z J Med. 1988;18(1):28-35.

    Not in our library10.1111/j.1445-5994.1988.tb02236.x (opens in a new tab)

  51. 51.

    Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab. 2005;90(5):2731-2739.

    Not in our library10.1210/jc.2004-2297 (opens in a new tab)

  52. 52.

    Miller A, Doll H, David J, Wass J. Impact of musculoskeletal disease on quality of life in long-standing acromegaly. Eur J Endocrinol. 2008;158(5):587-593.

    Not in our library10.1530/eje-07-0838 (opens in a new tab)

  53. 53.

    Colao A, Cannavo S, Marzullo P, Pivonello R, Squadrito S, Vallone G, Almoto B, Bichisao E, Trimarchi F, Lombardi G. Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly. Eur J Endocrinol. 2003;148(1):31-38.

    Not in our library10.1530/eje.0.1480031 (opens in a new tab)

  54. 54.

    Wassenaar MJ, Biermasz NR, Bijsterbosch J, Pereira AM, Meulenbelt I, Smit JW, Roelfsema F, Kroon HM, Romijn JA, Kloppenburg M. Arthropathy in long-term cured acromegaly is characterised by osteophytes without joint space narrowing: a comparison with generalised osteoarthritis. Ann Rheum Dis. 2011;70(2):320-325.

    Not in our library10.1136/ard.2010.131698 (opens in a new tab)

  55. 55.

    Mazziotti G, Bianchi A, Bonadonna S, Cimino V, Patelli I, Fusco A, Pontecorvi A, De Marinis L, Giustina A. Prevalence of vertebral fractures in men with acromegaly. J Clin Endocrinol Metab. 2008;93(12):4649-4655.

    Not in our library10.1210/jc.2008-0791 (opens in a new tab)

  56. 56.

    Battista C, Chiodini I, Muscarella S, Guglielmi G, Mascia ML, Carnevale V, Scillitani A. Spinal volumetric trabecular bone mass in acromegalic patients: a longitudinal study. Clin Endocrinol. 2009;70(3):378-382.

    Not in our library10.1111/j.1365-2265.2008.03322.x (opens in a new tab)

  57. 57.

    Mazziotti G, Gola M, Bianchi A, Porcelli T, Giampietro A, Cimino V, Doga M, Gazzaruso C, De Marinis L, Giustina A. Influence of diabetes mellitus on vertebral fractures in men with acromegaly. Endocrine. 2011;40(1):102-108.

    Not in our library10.1007/s12020-011-9486-x (opens in a new tab)

  58. 58.

    Rokkas T, Pistiolas D, Sechopoulos P, Margantinis G, Koukoulis G. Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. World J Gastroenterol. 2008;14(22):3484-3489.

    Not in our library10.3748/wjg.14.3484 (opens in a new tab)

  59. 59.

    Jenkins PJ, Fairclough PD. Screening guidelines for colorectal cancer and polyps in patients with acromegaly. Gut. 2002;51(Suppl 5):V13-V14.

    Not in our library10.1136/gut.51.suppl_5.v13 (opens in a new tab)

  60. 60.

    Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, Dash C, Giardiello FM, Glick S, Johnson D, Johnson CD, Levin TR, Pickhardt PJ, Rex DK, Smith RA, Thorson A, Winawer SJ. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134(5):1570-1595.

    Not in our library10.1053/j.gastro.2008.02.002 (opens in a new tab)

  61. 61.

    Dworakowska D, Gueorguiev M, Kelly P, Monson JP, Besser GM, Chew SL, Akker SA, Drake WM, Fairclough PD, Grossman AB, Jenkins PJ. Repeated colonoscopic screening of patients with acromegaly: 15-year experience identifies those at risk of new colonic neoplasia and allows for effective screening guidelines. Eur J Endocrinol. 2010;163(1):21-28.

    Not in our library10.1530/eje-09-1080 (opens in a new tab)

  62. 62.

    Ayuk J, Sheppard MC. Does acromegaly enhance mortality? Rev Endocr Metab Disord. 2008;9(1):33-39.

    Not in our library10.1007/s11154-007-9067-8 (opens in a new tab)

  63. 63.

    Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2008;93(1):61-67.

    Not in our library10.1210/jc.2007-1191 (opens in a new tab)

  64. 64.

    Sherlock M, Reulen RC, Alonso AA, Ayuk J, Clayton RN, Sheppard MC, Hawkins MM, Bates AS, Stewart PM. ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab. 2009;94(11):4216-4223.

    Not in our library10.1210/jc.2009-1097 (opens in a new tab)

  65. 65.

    Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119(11):3189-3202.

    Not in our library10.1172/jci39375 (opens in a new tab)

  66. 66.

    Brian SR, Bidlingmaier M, Wajnrajch MP, Weinzimer SA, Inzucchi SE. Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects. J Clin Endocrinol Metab. 2007;92(9):3374-3377.

    Not in our library10.1210/jc.2007-0997 (opens in a new tab)

  67. 67.

    Cheng S, Grasso L, Martinez-Orozco JA, Al-Agha R, Pivonello R, Colao A, Ezzat S. Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature. Clin Endocrinol. 2012;76(2):264-271.

    Not in our library10.1111/j.1365-2265.2011.04180.x (opens in a new tab)

  68. 68.

    Caron P, Broussaud S, Bertherat J, Borson-Chazot F, Brue T, Cortet-Rudelli C, Chanson P. Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women. J Clin Endocrinol Metab. 2010;95(10):4680-4687.

    Not in our library10.1210/jc.2009-2331 (opens in a new tab)

  69. 69.

    Cozzi R, Attanasio R, Barausse M. Pregnancy in acromegaly: a one-center experience. Eur J Endocrinol. 2006;155(2):279-284.

    Not in our library10.1530/eje.1.02215 (opens in a new tab)

  70. 70.

    Daly AF, Tichomirowa MA, Petrossians P, Heliovaara E, Jaffrain-Rea ML, Barlier A, Naves LA, Ebeling T, Karhu A, Raappana A, Cazabat L, De Menis E, Montanana CF, Raverot G, Weil RJ, Sane T, Maiter D, Neggers S, Yaneva M, Tabarin A, Verrua E, Eloranta E, Murat A, Vierimaa O, Salmela PI, Emy P, Toledo RA, Sabate MI, Villa C, Popelier M, Salvatori R, Jennings J, Longas AF, Labarta Aizpun JI, Georgitsi M, Paschke R, Ronchi C, Valimaki M, Saloranta C, De Herder W, Cozzi R, Guitelman M, Magri F, Lagonigro MS, Halaby G, Corman V, Hagelstein MT, Vanbellinghen JF, Barra GB, Gimenez-Roqueplo AP, Cameron FJ, Borson-Chazot F, Holdaway I, Toledo SP, Stalla GK, Spada A, Zacharieva S, Bertherat J, Brue T, Bours V, Chanson P, Aaltonen LA, Beckers A. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab. 2010;95(11):E373-E383.

    Not in our library10.1210/jc.2009-2556 (opens in a new tab)

  71. 71.

    Jaffrain-Rea ML, Daly AF, Angelini M, Petrossians P, Bours V, Beckers A. Genetic susceptibility in pituitary adenomas: from pathogenesis to clinical implications. Exp Rev Endocrinol Metab. 2011;6(2):195-214.

    Not in our library10.1586/eem.10.87 (opens in a new tab)

  72. 72.

    Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TM, Salmela PI, Paschke R, Gundogdu S, De Menis E, Makinen MJ, Launonen V, Karhu A, Aaltonen LA. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science. 2006;312(5777):1228-1230.

    Not in our library10.1126/science.1126100 (opens in a new tab)

  73. 73.

    Cazabat L, Libe R, Perlemoine K, Rene-Corail F, Burnichon N, Gimenez-Roqueplo AP, Dupasquier-Fediaevsky L, Bertagna X, Clauser E, Chanson P, Bertherat J, Raffin-Sanson ML. Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. Eur J Endocrinol. 2007;157(1):1-8.

    Not in our library10.1530/eje-07-0181 (opens in a new tab)

  74. 74.

    Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J, Stolbrink M, Christian HC, Wray J, Bishop-Bailey D, Berney DM, Wass JA, Popovic V, Ribeiro-Oliveira A, Gadelha MR, Monson JP, Akker SA, Davis JR, Clayton RN, Yoshimoto K, Iwata T, Matsuno A, Eguchi K, Musat M, Flanagan D, Peters G, Bolger GB, Chapple JP, Frohman LA, Grossman AB, Korbonits M. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab. 2008;93(6):2390-2401.

    Not in our library10.1210/jc.2007-2611 (opens in a new tab)

  75. 75.

    Carlsen SM, Lund-Johansen M, Schreiner T, Aanderud S, Johannesen O, Svartberg J, Cooper JG, Hald JK, Fougner SL, Bollerslev J. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab. 2008;93(8):2984-2990.

    Not in our library10.1210/jc.2008-0315 (opens in a new tab)

  76. 76.

    Mao ZG, Zhu YH, Tang HL, Wang DY, Zhou J, He DS, Lan H, Luo BN, Wang HJ. Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur J Endocrinol. 2010;162(4):661-666.

    Not in our library10.1530/eje-09-0908 (opens in a new tab)

  77. 77.

    Shen M, Shou X, Wang Y, Zhang Z, Wu J, Mao Y, Li S, Zhao Y. Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study. Endocr J. 2010;57(12):1035-1044.

    Not in our library10.1507/endocrj.k10e-203 (opens in a new tab)

  78. 78.

    Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clin Endocrinol. 2007;67(2):310-315.

    Not in our library10.1111/j.1365-2265.2007.02885.x (opens in a new tab)

  79. 79.

    Karavitaki N, Turner HE, Adams CB, Cudlip S, Byrne JV, Fazal-Sanderson V, Rowlers S, Trainer PJ, Wass JA. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin Endocrinol. 2008;68(6):970-975.

    Not in our library10.1111/j.1365-2265.2007.03139.x (opens in a new tab)

  80. 80.

    Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes-Socin H, Stevenaert A, Chanson P, Beckers A. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol. 2005;152(1):61-66.

    Not in our library10.1530/eje.1.01824 (opens in a new tab)

  81. 81.

    Gola M, Bonadonna S, Mazziotti G, Amato G, Giustina A. Resistance to somatostatin analogs in acromegaly: an evolving concept? J Endocrinol Invest. 2006;29(1):86-93.

    Not in our library10.1007/bf03349183 (opens in a new tab)

  82. 82.

    Buchfelder M. Management of aggressive pituitary adenomas: current treatment strategies. Pituitary. 2009;12(3):256-260.

    Not in our library10.1007/s11102-008-0153-z (opens in a new tab)

  83. 83.

    Colao A, Auriemma RS, Lombardi G, Pivonello R. Resistance to somatostatin analogs in acromegaly. Endocr Rev. 2011;32(2):247-271.

    Not in our library10.1210/er.2010-0002 (opens in a new tab)

  84. 84.

    Swords FM, Monson JP, Besser GM, Chew SL, Drake WM, Grossman AB, Plowman PN. Gamma knife radiosurgery: a safe and effective salvage treatment for pituitary tumours not controlled despite conventional radiotherapy. Eur J Endocrinol. 2009;161(6):819-828.

    Not in our library10.1530/eje-09-0493 (opens in a new tab)

  85. 85.

    Giustina A, Bronstein MD, Casanueva FF, Chanson P, Ghigo E, Ho KK, Klibanski A, Lamberts S, Trainer P, Melmed S. Current management practices for acromegaly: an international survey. Pituitary. 2011;14(2):125-133.

    Not in our library10.1007/s11102-010-0269-9 (opens in a new tab)

  86. 86.

    Clemmons DR. Clinical laboratory indices in the treatment of acromegaly. Clin Chim Acta. 2011;412(5–6):403-409.

    Not in our library10.1016/j.cca.2010.11.008 (opens in a new tab)

  87. 87.

    Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab. 1998;83(10):3411-3418.

    Not in our library10.1210/jc.83.10.3411 (opens in a new tab)

  88. 88.

    Salaun C, Foubert L, Vialatou M, Kujas M, Turpin G. Prognostic factors in the surgical management of acromegaly. Ann Med Interne. 1999;150(3):195-198.

    Not in our library

  89. 89.

    van der Lely AJ, Harris AG, Lamberts SW. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. Clin Endocrinol. 1992;37(2):181-185.

    Not in our library10.1111/j.1365-2265.1992.tb02304.x (opens in a new tab)

  90. 90.

    Asa SL, Digiovanni R, Jiang J, Ward ML, Loesch K, Yamada S, Sano T, Yoshimoto K, Frank SJ, Ezzat S. A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer Res. 2007;67(15):7505-7511.

    Not in our library10.1158/0008-5472.can-07-0219 (opens in a new tab)

  91. 91.

    Jaffrain-Rea ML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, Santoro A, Faticanti Scucchi L, Gulino A, Cantore G. A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer. 2002;9(2):103-113.

    Not in our library10.1677/erc.0.0090103 (opens in a new tab)

  92. 92.

    Kitz K, Knosp E, Koos WT, Korn A. Proliferation in pituitary adenomas: measurement by MAb KI 67. Acta Neurochir Suppl. 1991;53:60-64.

    Not in our library10.1007/978-3-7091-9183-5_11 (opens in a new tab)

  93. 93.

    Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD, Melmed S. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab. 1999;84(2):761-767.

    Not in our library10.1210/jc.84.2.761 (opens in a new tab)

  94. 94.

    Kiseljak-Vassiliades K, Shafi S, Kerr JM, Phang TL, Kleinschmidt-Demasters BK, Wierman ME (2012) Clinical implications of growth hormone-secreting tumor subtypes. Endocrine 42(1):18–28

    Not in our library10.1007/s12020-012-9660-9 (opens in a new tab)

  95. 95.

    Bando H, Sano T, Ohshima T, Zhang CY, Yamasaki R, Matsumoto K, Saito S. Differences in pathological findings and growth hormone responses in patients with growth hormone-producing pituitary adenoma. Endocrinol Jpn. 1992;39(4):355-363.

    Not in our library10.1507/endocrj1954.39.355 (opens in a new tab)

  96. 96.

    Ezzat S, Kontogeorgos G, Redelmeier DA, Horvath E, Harris AG, Kovacs K. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. Eur J Endocrinol. 1995;133(6):686-690.

    Not in our library10.1530/eje.0.1330686 (opens in a new tab)

  97. 97.

    Marazuela M, Paniagua AE, Gahete MD, Lucas T, Alvarez-Escola C, Manzanares R, Cameselle-Teijeiro J, Luque-Ramirez M, Luque RM, Fernandez-Rodriguez E, Castano JP, Bernabeu I. Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study. J Clin Endocrinol Metab. 2011;96(2):E251-E259.

    Not in our library10.1210/jc.2010-1742 (opens in a new tab)

  98. 98.

    Mazal PR, Czech T, Sedivy R, Aichholzer M, Wanschitz J, Klupp N, Budka H. Prognostic relevance of intracytoplasmic cytokeratin pattern, hormone expression profile, and cell proliferation in pituitary adenomas of akromegalic patients. Clin Neuropathol. 2001;20(4):163-171.

    Not in our library

  99. 99.

    Ahmed E, Stratton P, Adams W. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol. 1999;50(5):561-567.

    Not in our library10.1046/j.1365-2265.1999.00760.x (opens in a new tab)

  100. 100.

    Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol. 2003;58(1):86-91.

    Not in our library10.1046/j.1365-2265.2003.01679.x (opens in a new tab)

  101. 101.

    Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, Lodrini A, Lombardi G, Cozzi R. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2006;91(1):85-92.

    Not in our library10.1210/jc.2005-1208 (opens in a new tab)

  102. 102.

    De P, Rees DA, Davies N, John R, Neal J, Mills RG, Vafidis J, Davies JS, Scanlon MF. Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission. J Clin Endocrinol Metab. 2003;88(8):3567-3572.

    Not in our library10.1210/jc.2002-021822 (opens in a new tab)

  103. 103.

    Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur J Endocrinol. 2005;152(3):379-387.

    Not in our library10.1530/eje.1.01863 (opens in a new tab)

  104. 104.

    Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF, Sandler HM. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab. 1997;82(10):3187-3191.

    Not in our library10.1210/jc.82.10.3187 (opens in a new tab)

  105. 105.

    Cozzi R, Barausse M, Asnaghi D, Dallabonzana D, Lodrini S, Attanasio R. Failure of radiotherapy in acromegaly. Eur J Endocrinol. 2001;145(6):717-726.

    Not in our library10.1530/eje.0.1450717 (opens in a new tab)

  106. 106.

    Izawa M, Hayashi M, Nakaya K, Satoh H, Ochiai T, Hori T, Takakura K. Gamma knife radiosurgery for pituitary adenomas. J Neurosurg. 2000;93(Suppl 3):19-22.

    Not in our library10.3171/jns.2000.93.supplement (opens in a new tab)

  107. 107.

    Arosio M, Macchelli S, Rossi CM, Casati G, Biella O, Faglia G, Italian Multicenter Octreotide Study Group. Effects of treatment with octreotide in acromegalic patients–a multicenter Italian study. Eur J Endocrinol. 1995;133(4):430-439.

    Not in our library10.1530/eje.0.1330430 (opens in a new tab)

  108. 108.

    Bevan JS. Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab. 2005;90(3):1856-1863.

    Not in our library10.1210/jc.2004-1093 (opens in a new tab)

  109. 109.

    Clemmons DR, Chihara K, Freda PU, Ho KK, Klibanski A, Melmed S, Shalet SM, Strasburger CJ, Trainer PJ, Thorner MO. Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab. 2003;88(10):4759-4767.

    Not in our library10.1210/jc.2003-030518 (opens in a new tab)

  110. 110.

    Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook DM, Malarkey WB, Jackson I, Vance ML, Thorner MO, Barkan A, Frohman LA, Melmed S, et al. Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med. 1992;117(9):711-718.

    Not in our library10.7326/0003-4819-117-9-711 (opens in a new tab)

  111. 111.

    Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2002;87(7):3013-3018.

    Not in our library10.1210/jc.87.7.3013 (opens in a new tab)

  112. 112.

    Giusti M, Ciccarelli E, Dallabonzana D, Delitala G, Faglia G, Liuzzi A, Gussoni G, Giordano Disem G. Clinical results of long-term slow-release lanreotide treatment of acromegaly. Eur J Clin Invest. 1997;27(4):277-284.

    Not in our library10.1046/j.1365-2362.1997.1190659.x (opens in a new tab)

  113. 113.

    Abe T, Ludecke DK. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol. 2001;145(2):137-145.

    Not in our library10.1530/eje.0.1450137 (opens in a new tab)

  114. 114.

    Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S, Lombardi G. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab. 2006;91(6):2112-2118.

    Not in our library10.1210/jc.2005-2110 (opens in a new tab)

  115. 115.

    Lucas T, Astorga R, Catala M. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol. 2003;58(4):471-481.

    Not in our library10.1046/j.1365-2265.2003.01741.x (opens in a new tab)

  116. 116.

    Verhelst JA, Pedroncelli AM, Abs R, Montini M, Vandeweghe MV, Albani G, Maiter D, Pagani MD, Legros JJ, Gianola D, Bex M, Poppe K, Mockel J, Pagani G. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol. 2000;143(5):577-584.

    Not in our library10.1530/eje.0.1430577 (opens in a new tab)

Cited by papers we hold 4

Questions about this paper

We email you if it is retracted, withdrawn, corrected or flagged.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.